Is Intellia Therapeutics a Buy?
There's a clear distinction between the three pioneering companies developing genetic medicines based on CRISPR gene editing tools. CRISPR Therapeutics (NASDAQ: CRSP), valued at $2.7 billion, was the first to advance a drug to clinical trials, and it has ample support from its deep-pocketed partner, Vertex Therapeutics (NASDAQ: VRTX). Editas Medicine (NASDAQ: EDIT) is valued at $1.3 billion and was the second to advance a drug to clinical trials, but it's experienced some executive churn and doesn't have a big partner for its lead program.
And then there's Intellia Therapeutics (NASDAQ: NTLA). The business is valued at $850 million, won't have a drug candidate in clinical trials until 2020 or 2021, and has only named one pipeline asset to date (though it does have a deep-pocketed partner). Investors are clearly not quite as excited for the laggard as they are for its peers, but the company might have a trick up its sleeve investors are overlooking. Does a relatively low market cap make Intellia Therapeutics a buy?
Image source: Getty Images.
Quelle Fool.com
